advertisement
Kahook MY 22
Showing records 1 to 22 | Display all abstracts from Kahook MY79961 Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)
Kahook MY
American Journal of Ophthalmology 2019; 200: 130-137
79871 Tolerability and Functionality of a Wireless 24-Hour Ocular Telemetry Sensor in African American Glaucoma Patients
Marando CM
Journal of Glaucoma 2019; 28: 119-124
79492 24-Hour Intraocular Pressure Control with Fixed-dose Combination Brinzolamide 1%/Brimonidine 0.2%: A Multicenter, Randomized Trial
Weinreb RN
Ophthalmology 2019; 126: 1095-1104
79660 Current opinion in ophthalmology: novel glaucoma devices in the pipeline
Ittoop SM
Current Opinions in Ophthalmology 2019; 30: 117-124
79871 Tolerability and Functionality of a Wireless 24-Hour Ocular Telemetry Sensor in African American Glaucoma Patients
Mansouri K
Journal of Glaucoma 2019; 28: 119-124
79961 Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)
Serle JB
American Journal of Ophthalmology 2019; 200: 130-137
79492 24-Hour Intraocular Pressure Control with Fixed-dose Combination Brinzolamide 1%/Brimonidine 0.2%: A Multicenter, Randomized Trial
Bacharach J
Ophthalmology 2019; 126: 1095-1104
79660 Current opinion in ophthalmology: novel glaucoma devices in the pipeline
Seibold LK
Current Opinions in Ophthalmology 2019; 30: 117-124
79871 Tolerability and Functionality of a Wireless 24-Hour Ocular Telemetry Sensor in African American Glaucoma Patients
Kahook MY
Journal of Glaucoma 2019; 28: 119-124
79961 Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)
Mah FS
American Journal of Ophthalmology 2019; 200: 130-137
79660 Current opinion in ophthalmology: novel glaucoma devices in the pipeline
Kahook MY
Current Opinions in Ophthalmology 2019; 30: 117-124
79492 24-Hour Intraocular Pressure Control with Fixed-dose Combination Brinzolamide 1%/Brimonidine 0.2%: A Multicenter, Randomized Trial
Fechtner RD; Kahook MY
Ophthalmology 2019; 126: 1095-1104
79961 Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)
Kim T
American Journal of Ophthalmology 2019; 200: 130-137
79871 Tolerability and Functionality of a Wireless 24-Hour Ocular Telemetry Sensor in African American Glaucoma Patients
Seibold LK
Journal of Glaucoma 2019; 28: 119-124
79492 24-Hour Intraocular Pressure Control with Fixed-dose Combination Brinzolamide 1%/Brimonidine 0.2%: A Multicenter, Randomized Trial
Wirta D
Ophthalmology 2019; 126: 1095-1104
79961 Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)
Raizman MB
American Journal of Ophthalmology 2019; 200: 130-137
79492 24-Hour Intraocular Pressure Control with Fixed-dose Combination Brinzolamide 1%/Brimonidine 0.2%: A Multicenter, Randomized Trial
Burmaster S
Ophthalmology 2019; 126: 1095-1104
79961 Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)
Heah T; Ramirez-Davis N
American Journal of Ophthalmology 2019; 200: 130-137
79492 24-Hour Intraocular Pressure Control with Fixed-dose Combination Brinzolamide 1%/Brimonidine 0.2%: A Multicenter, Randomized Trial
Meng X
Ophthalmology 2019; 126: 1095-1104
79961 Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)
Kopczynski CC
American Journal of Ophthalmology 2019; 200: 130-137
79492 24-Hour Intraocular Pressure Control with Fixed-dose Combination Brinzolamide 1%/Brimonidine 0.2%: A Multicenter, Randomized Trial
Hubatsch DA
Ophthalmology 2019; 126: 1095-1104
79961 Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)
Usner DW; Novack GD;
American Journal of Ophthalmology 2019; 200: 130-137
